<DOC>
	<DOCNO>NCT01873534</DOCNO>
	<brief_summary>The trial uncontrolled , open-label , parallel group clinical trial . Approximately 10 subject per dose group 3 group treat twice weekly total 9 dos , follow 4-week observation period . Eligible subject Hgb ≥10.5 g/dL stable Hgb level start washout period one eight week . During washout period , 30 subject whose Hgb &lt; 10.0 complete baseline assessment confirm eligibility . Eligible subject randomly assign one 3 cohort 1:1:1 ratio . Subjects admit day first dose stay clinic overnight pharmacokinetic ( PK ) sample first ( day 1 ) last dose ( day 29 ) . FMX-8 administer 30 min i.v . infusion . After 29-day treatment period , trial subject observe additional 28 day allow safety immunogenicity assessment .</brief_summary>
	<brief_title>A Phase 2A Trial FMX-8 Treatment Anemia Patients With ESRD Hemodialysis HD</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Male female patient ≥18 year old Diagnosed ESRD stable hemodialysis 3 month Maintained stable Hgb ≥4 week prior screen Two consecutive Hgb value ≥10.5 g/dL within 5 week screen Body mass index ( BMI ) 18 kg/m2 42 kg/m2 , inclusive , base upon late height weight Ferritin level ≥100 mg/L Tsat ≥20 % reticulocyte hemoglobin content ( CHr ) &gt; 25 screen Reasonable clearance dialysis ( KT/V ≥1.0 ) two prior determination within 2.5 month Able provide write informed consent Able understand follow trial procedure Willing use contraception detail protocol Hgb remain unchanged without erythropoietin ( &lt; 0.5 g/dL decrease 8 week maximum erythropoietinwashout period ) Receipt iron infusion initiation erythropoietin washout Receipt red blood cell transfusion within four week screen Overt gastrointestinal bleeding bleed episode require transfusion within 2 month prior screen Infection necessitate antibiotic antiviral treatment within month prior screen Requirement Coumadin ( warfarin ) , Pradaxa Xarelto Hemoglobinopathies homozygous sicklecell disease thalassemia type Active hemolysis chronic hypoxia Active malignant disease ( except nonmelanoma skin cancer ) life expectancy le 6 month Chronic , uncontrolled symptomatic inflammatory disease nonrenal cause anemia rheumatoid arthritis , systemic lupus erythematosus , HIV , systemic acute infection On immunosuppressive therapeutic Chronic congestive heart failure ( New York Heart Association Class III , IV ) Significant hypertension ( ≥90 diastolic ) base sit diastolic blood pressure screen Kidney transplant within past year : patient immunosuppressive agent follow fail transplant eligible trial Endstage liver disease Known hypersensitivity recombinant protein therapy Female patient pregnant breast feed Previous exposure FMX8 Exposure Omontys® Hematide® ( peginesatide ) anemia treatment within past 6 month Treatment Aranesp® ( darbepoetin alpha ) within past 4 week Uncontrolled hyperparathyroidism ( PTH &gt; 750 ) base upon late PTH determination within past 4 month Inability comply trial schedule visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Anemia</keyword>
</DOC>